Expanded Clinical Study Confirms Natural GLP-1 Support from Dyglomera and CQR-300

Fairfield, CA – January 8, 2026 – Gateway Health Alliances today announced the peer-reviewed publication in Medicina of updated clinical results showing that its patented botanical extracts, Dyglomera® (Dichrostachys glomerata) and CQR-300® (Cissus quadrangularis), significantly increased natural GLP-1 levels by inhibiting DPP-4 activity.

In the 16-week, randomized, double-blind, placebo-controlled clinical trial involving 248 overweight and obese adults (BMI 25–34.9), subjects taking Gateway ingredients (300 mg Dyglomera® or 400 mg CQR-300® daily) experienced meaningful weight loss, improved body composition, and enhanced markers of metabolic health, without prescribed dietary restriction, compared to placebo.

The study is among the larger human studies evaluating standardized botanical extracts for GLP-1/DPP-4 outcomes. Results confirmed and extended initial findings presented in 2024 at the International Conference of the Functional Food Center, San Diego.

• Increased active GLP-1 levels. At week 16, 3-hour postprandial active GLP-1 increased by +38.6 pg/mL (+294.7%) with Dyglomera® and +42.2 pg/mL (+321.4%) with CQR-300®, compared to +4.7 pg/mL (+36.1%) with placebo.

• Inhibited DPP-4 enzyme activity. DPP-4 activity decreased by 15.3% with Dyglomera® and 17.8% with CQR-300®, versus a 2.9% reduction in the placebo group, supporting increased endogenous GLP-1 availability.

• Clinically meaningful weight and body-fat reduction. Participants experienced average body-weight reductions of 5.2% (Dyglomera®) and 5.8% (CQR-300®), alongside body-fat reductions of 10.3% and 10.9%, respectively, compared with 0.7% weight loss and 1.5% fat loss in the placebo group.

• Reduced calorie intake and enhanced satiety. Daily energy intake decreased by 16.2% (Dyglomera®) and 17.5% (CQR-300®) versus 3.1% with placebo, while subjective satiety scores increased by 25.6% and 27.4%, respectively, compared to 5.3% with placebo.

• Improved metabolic biomarkers. Both botanical extracts significantly reduced fasting glucose, triglycerides, and total cholesterol. Changes in LDL-C and HDL-C were modest and did not reach statistical significance.

“This expanded trial demonstrates the consistency and strength of our science,” said Shil Kothari, President of Gateway Health Alliances. “Dyglomera and CQR-300 were shown to increase GLP-1 and reduce DPP-4 activity over 16 weeks, supporting multiple aspects of metabolic health—all in low daily doses suitable for food, beverage, and supplement applications.”

A Robust Body of Clinical Evidence

The publication adds to a robust body of evidence: more than 10 human clinical studies involving over 1,000 participants have demonstrated that Dyglomera® and CQR-300® support appetite regulation, improve body composition, and enhance metabolic balance. The new findings establish GLP-1/DPP-4 modulation as a key mechanism of action, complementing earlier research showing effects on other hormones—including leptin, adiponectin, and insulin—that are central to appetite and satiety regulation.

Dr. Julius Enyong Oben, Professor of Nutritional Biochemistry at the University of Yaoundé and lead investigator, commented: “We now have the strongest evidence yet that these extracts support GLP-1 activity through natural pathways in the body, helping regulate appetite, reduce body fat, and improve key markers of metabolic health. This positions Dyglomera and CQR-300 as breakthrough natural options for global weight-management and metabolic-wellness strategies.”

Study Citation

Youovop J, Takuissu G, Minoue R, et al. Effects of Dichrostachys glomerata and Cissus quadrangularis extracts on GLP-1 secretion and DPP-4 activity in overweight and obese individuals: a randomized controlled trial. Medicina. 2026;62(1):41. doi:10.3390/medicina62010041